Carlon Colker

Colker previously served as a researcher and television spokesperson for “V-Factor” (a combination of yohimbine, L-arginine, and Gingko biloba), a dietary supplement marketed by Vital Basics, Inc. of Portland, Maine as a men’s sexual performance enhancer. In 2004, the U.S. Federal Trade Commission registered a complaint against Vital Basics and its owners alleging, in part, that the company’s advertising of V-Factor violated Federal law; specifically, that the company made unsubstantiated claims about V-Factor’s safety; falsely represented that a clinical study of V-Factor conducted by Colker proved that the product was safe and effective; and misrepresented paid commercial advertising featuring Colker (Vital Basics Health Show radio infomercials) as independent radio programs. The defendants settled the FTC’s complaint by paying $1 million for consumer redress and agreeing not to make unsubstantiated claims in the future.

Colker became the personal trainer of NBA player Kristaps Porzingis in 2017. Some critics have expressed skepticism regarding Colker's involvement due to his past supplement controversies.

In January 2015, Justin Bieber said he used MYO-X in preparation for a Calvin Klein underwear photo shoot and thanked Colker over social media; Bieber was criticized for “…hyping Colker’s latest “miracle” supplement MYO-X, to his 59 million Twitter fans.”

SEC documents filed by the manufacturer (MYOS Corp.; dba Atlas Therapeutics until May 2012), indicate that the product consists of a powder isolated from the yolk of fertilized chicken eggs. It was developed by Colker in 2005 as a supplement formulation that was marketed initially under the trade name Folstaxan by Celldyne Biopharma LLC and, subsequently, under the trade name MYO-T12 by Atlas/MYOS.

In February 2011, Colker served as chief medical officer and executive vice president of Atlas Therapeutics Corp. (OTCBB: ATTH; formerly Marvin's Place, Inc.; dba MYOS Corp. as of May 2012; OTCBB:MYOS). In June 2012, Colker resigned his position and became a member of the company's scientific advisory board. In 2008, it was announced that Colker would be serving on the advisory board of the multi-level marketing company LifeVantage. In 2005, Colker was named as head of the scientific advisory board of the dietary supplement company Health Sciences Group (OTCBB:HESG), and in 2006 the company announced that Colker would be assisting in the formulation of the supplement product Sequestrol. Colker was also a product developer and spokesperson for the dietary supplement Lipistat, marketed by ITV Ventures.

In February 2011, Colker sold the marketing rights and trademarks for MYO-T12 to MYOS for $1.15 million and entered into a three-year employment agreement to serve as the company’s Chief Medical Officer and Executive vice-president, resigning in 2012 to serve as a scientific advisor for the company in exchange for 300,000 shares of common stock. Under the terms of licensing agreements with MYOS, MYO-T12 is distributed by Maximum Human Performance (MHP) under the brand name MYO-X, and by Cenegenics (NASDAQ:CELG) under the brand name Cenegenics Muscle Formula (Fortetropin).

In 2008, Colker made news headlines after advising actor Jeremy Piven to prematurely withdraw from David Mamet's Broadway play Speed-the-Plow due to concerns of alleged mercury poisoning from consuming excessive amounts of sushi and Chinese herbal supplement products.

In 2008, Colker advised actor Jeremy Piven to prematurely withdraw from David Mamet’s Broadway play Speed-the-Plow due to concerns of alleged mercury poisoning from consuming excessive amounts of sushi and Chinese herbal supplement products. The producers of the show pursued grievance and arbitration hearings through the Actors Equity union, which ruled in Piven’s favor.

Following the February 2003 heatstroke-related death of Baltimore Orioles pitcher Steve Bechler, in which ephedra was implicated as the cause, Colker and two other physicians, all speaking on behalf of the industry-affiliated Ephedra Education Council, disputed the role that ephedra played in Bechler’s death. Colker also downplayed the dangers of ephedra, claiming that it "is not a health risk for most people".

In May 2003, a California Superior Court judge handed down a $12.5 million judgment in a class action suit against Cytodyne Technologies for falsely advertising Xenadrine RFA-1, the product implicated in the death of Bechler. Colker had been enlisted by Cytodyne to conduct a clinical study on the effectiveness of Xenadrine RFA-1, and upon the study’s completion, the company paid Colker approximately $5,000 to field calls from customers and make conference appearances. Referring to Colker's research, the judge noted that Colker lacked credibility and concluded that Cytodyne had "not just exaggerated the findings of the clinical trials it commissioned, but had also cajoled some researchers into fudging results", and that those involved in the research on Xenadrine RFA-1 had set out "to create a study that justified the money being spent by Cytodyne and that would ensure that they received further work from the company". Journalists for The New York Times commenting on Cytodyne's research noted that the legal case raised "serious questions about the way makers of ephedra and other dietary supplements use -- and often misuse -- the promise of scientific proof to market their products".

During 2003, Colker was named as a defendant in lawsuits filed in Missouri, West Virginia, and Illinois in connection with his involvement in the research and marketing of Hydroxycut and Xenadrine RFA-1. The lawsuits alleged that Colker and his Greenwich clinic, Peak Wellness Inc., ran fraudulent tests, altered test results, and hid dangerous adverse reactions suffered by test subjects. In July 2003, Colker was called to testify before a United States House Committee on Energy and Commerce investigating deaths and adverse events stemming from ephedra supplements for which Colker had been involved in researching and marketing. In August 2004 his lawyers said he had been dropped from the Missouri lawsuit and talks were underway to release him from the others; the report did not describe the agreement under which he was dropped.

In the early 2000s, Colker was criticized for his research and commentary in relation to dietary supplements including ephedra-based products, amongst others. He was a defendant named in lawsuits filed in multiple U.S. states alleging that research he conducted on behalf of the ephedra supplement manufacturers Cytodyne Technologies and Metabolife was fraudulent; that he had altered test results, and that he had attempted to hide dangerous adverse reactions suffered by research subjects. In 2004, Colker appeared in radio commercials for V-Factor, a dietary supplement that claimed to enhance male sexual performance, which were the focus of a false advertising complaint against Vital Basics, Inc. by the U.S. Federal Trade Commission.

In 1996, Colker was employed first at Park Avenue Medical Nutrition and then later that year, by Affiliated Physicians, both located in New York City. In January 1996 he established Peak Wellness, a company with locations in Greenwich, Connecticut and Beverly Hills, California that provides integrative medical services. Colker is an affiliate of Greenwich Hospital in Greenwich, Connecticut. and is an attending physician in the Department of Medicine at Mount Sinai Beth Israel Hospital in New York City. Colker also serves as a voluntary faculty member (clinical assistant professor of medicine in neurology) at Weill Cornell Medical College in New York City.

Colker received a baccalaureate degree in June 1988 from Manhattanville College in Purchase, New York. He received his medical degree in May 1993 from Sackler School of Medicine. From 1993 to 1996, he received residency training in internal medicine at Beth Israel Medical Center in Manhattan, New York.

Carlon M. Colker (born June 21, 1965) is an American celebrity doctor and dietary supplement industry consultant. He is the founder of Peak Wellness, Inc., a private practice and consulting company in Greenwich, Connecticut, and was the chief medical officer and executive vice president for the dietary supplement company Atlas Therapeutics (doing business as MYOS Corp.). He has also been a researcher, product developer, and spokesman for other supplement companies including LifeVantage, ITV Ventures, Cytodyne Technologies, Muscletech Research and Development, Metabolife International, and Vital Basics.